Author Index to Volume 54

Abi-Dargham A. *See* Simpson HB
Ackenheil M. *See* Willeit M
Adams LF. *See* Smith MJ
Addington J. *See* Woods SW
Adolfsson R. *See* Claes S
Akechi T. *See* Matusoka Y
Alakare B. *See* Joyal CC
Alberati D. *See* Le Pen G
Alger JR. *See* Levitt JG
Allison KC. *See* Stunkard AJ
Alphs L. *See* Potkin SG
Altar CA, Whitehead RE, Chen R, Wörtwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain, 703
Anand A. *See* Kugaya A
Anand R. *See* Potkin SG
Andersen SL. *See* Carlezon WA Jr
Anderson G. *See* Bremner JD
Andreasen NC. *See* Milev P; White T
Angelone SM. *See* Cavallaro R
Anghelescu I. *See* Schumann G
Anisman H. *See* Merali Z
Ansorge MS. *See* Lira A
Arajärvi R. *See* Tuulio-Henriksson A
Arango V. *See* Lira A
Arinami T. *See* Takahashi S
Arndt S. *See* Milev P
Arnow B. *See* Gelenberg AJ; Rush AJ
Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder, 1465
Ascher J. *See* Learned-Coughlin SM
Atkinson L. *See* Goldberg S
Auh S. *See* Pierri JN
Averland B. *See* Vaiva G
Avramopoulos D. *See* McInnis MG

Badner JA. *See* McInnis MG
Bailey A. *See* Stojanov W
Bajbouj M. *See* Gallinat J
Baldwin RM. *See* Kugaya A
Balija M. *See* Hranilovic D
Banerjee SP. *See* Smith EA
Banks P. *See* Gelenberg AJ
Barbini B. *See* Benedetti F
Bar-Haim Y, Marshall PJ, Fox NA, Schorr EA, Gordon-Salant S. Mismatch negativity in socially withdrawn children, 17
Barkai G. *See* Bonne O
Barrot M. *See* Bolaños CA; Eisch AJ
Barry RJ. *See* Dimoska A
Basile VS. *See* Goldberg S
Bassi T. *See* Cavallaro R
Baumgartner A. *See* Pinna G
Baumgartner T. *See* Heinrichs M
Bellodi L. *See* Cavallaro R
Benassi F. *See* Tecchio F
Bender BG. *See* Kelser SR
Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A, Barbini B, Smeraldi E. Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene, 687
Benson BE. *See* Speer AM
Bergström M. *See* Learned-Coughlin SM
Berton O. *See* Bolaños CA
Betan E. *See* Musselman DL
Better W. *See* Contoreggi C
Bhagwagar Z, Montgomery AJ, Grasby PM, Cowen PJ. Lack of effect of a single dose of hydrocortisone on serotonin1A receptors in recovered depressed patients measured by positron emission tomography with [11C]WAy-100635, 890
Bhandari R. *See* Smith EA
Biederman J. *See* Smoller JW; Wilens TE
Bilker WB. *See* Ragland JD
Bissette G. *See* Sautter FJ
Blanton RE. *See* Levitt JG
Blasey CM. *See* Kelser SR
Blitchington T. *See* Vythilingam M
Blumberg HP. *See* Donegan NH
Bohus M. *See* van Elst LT
Bolaños CA. *See* Eisch AJ
Bolaños CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood, 1317
Bondy B. *See* Schumann G; Willeit M
Bonne O, Gilboa A, Louzoun Y, Brandes D, Yona I, Lester H, Barkai G, Freedman N, Chisin R, Shalev AY. Resting regional cerebral perfusion in recent posttraumatic stress disorder, 1077
Borian FE. *See* Gelenberg AJ
Borroni E. *See* Le Pen G
Bowman ES. *See* McInnis MG
Bozkurt A. *See* Kugaya A
Bradley MM. *See* Shapira NA
Bradley-Moore M. *See* Lira A
Brambilla P, Nicoletti MA, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Magnetic resonance imaging study of corpus callosum abnormalities in patients with bipolar disorder, 1294
Brammer MJ. *See* Kumari V; Uher R
Brandes D. *See* Bonne O
Brandis D. *See* Zörner B
Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons, 1338
Breier A. *See* Woods SW
Bremner JD. *See* Schmahl CG; Vermetten E
Bremner JD, Vythilingam M, Anderson G, Vermetten E, McGlashan T, Heninger G, Rasmusson A, Southwick SM, Charney DS. Assessment of the hypothalamic-pituitary-adrenal axis over a 24-hour diurnal period and in response to neuroendocrine challenges in women with and without childhood sexual abuse and posttraumatic stress disorder, 710
Broedel O. *See* Pinna G
Brown RG. *See* Kumari V
Brown S. *See* Wilens TE
Brown WE. *See* Kelser SR

Abbreviations:
ed: editorial
comm: commentary
corr: correspondence

© 2003 Society of Biological Psychiatry

0006-3223/03/$30.00
PII S0006-3223(03)01164-8

Brunet A. *See* Vaiva G

Cadet JL. *See* Contoreggi C
Campbell IC. *See* Uher R
Campbell LC, Clauw DJ, Keefe FJ. Persistent pain and depression: a biopsychosocial perspective, 399
Cannon T. *See* Tuulio-Henriksson A
Cannon TD. *See* Johnson JK; Kieseppä T
Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH. Interferon-alpha–induced changes in tryptophan metabolism: relationship to depressino and paroxetine treatment, 906
Carlezon WA Jr, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats, 1330
Carlson J. *See* Teale P
Carmody TJ. *See* Rush AJ
Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease, 241
Carr V. *See* Stojanov W
Caspi A. *See* Weiser M
Castanon N. *See* Lira A
Castensson A, Emilsson L, Sundberg R, Jazin E. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis, 1212
Castner SA, Goldman-Rakic PS. Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates, 105
Cauley JA. *See* Yaffe K
Cavallaro R, Cavedini P, Mistretta P, Bassi T, Angelone SM, Ubbiali A, Bellodi L. Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study, 437
Cavedini P. *See* Cavallaro R
Cavus I, Duman RS. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats, 59
Cerbone A. *See* Sautter FJ
Charles HC. *See* Vythilingam M
Charney DS. *See* Bremner JD; Evans DL; Kugaya A; Vermetten E
Checkley SA. *See* Kumari V
Chellis JL. *See* McInnis MG
Chen R. *See* Altar CA
Chisin R. *See* Bonne O
Chong S-A. *See* Tan E-C
Choukèr M. *See* Pogarell O
Chrousos G. *See* Contoreggi C
Cirillo S. *See* Seifritz E
Claes S, Villafuerte S, Forsgren T, Sluijs S, Del-Favero J, Adolfsson R, Van Broeckhoven C. The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden, 867
Clarke AR. *See* Dimoska A
Clauw DJ. *See* Campbell LC
Coe CL, Kramer M, Czéh B, Gould E, Reeves AJ, Kirschbaum C, Fuchs E. Prenatal stress diminishes neurogenesis in the dentate gyrus of juvenile rhesus monkeys, 1025
Cohen BM. *See* Kaufman MJ; Silveri MM
Cohen JD. *See* Condray R
Cole SW, Kemeny ME, Fahey JL, Zack JA, Naliboff BD. Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system, 1444
Colombo C. *See* Benedetti F
Condray R, Siegle GJ, Cohen JD, van Kammen DP, Steinhauer SR. Automatic activation of the semantic network in schizophrenia: evidence from event-related brain potentials, 1134
Constable RT. *See* Shaywitz SE
Contoreggi C, Herning RI, Na P, Gold PW, Chrousos G, Negro PJ, Better W, Cadet JL. Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease, 873
Coplan D. *See* Mathew SJ
Coppola R. *See* Winterer G
Cordero I. *See* Sandi C
Court JA. *See* Martin-Ruiz CM
Cowen MS. *See* Schumann G
Cowen PJ. *See* Bhagwagar Z
Crawley JN. *See* Holmes A
Croyle RT, Rowland JH. Mood disorders and cancer: a National Cancer Institute perspective, 191=comm
Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease, 307
Cryan JF, Hoyer D, Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents, 49
Csernansky JG. *See* Tepest R
Cui Y-H. *See* Takahashi S
Czéh B. *See* Coe CL

Dahmen N. *See* Schumann G
Dai D. *See* Smoller JW
Damico KE. *See* Silveri MM
Dammann G. *See* Seifritz E
Daube-Witherspoon M. *See* Speer AM
Davidson M. *See* Weiser M
Davis KL. *See* Martin-Ruiz CM
de Jongh R, Groenink L, van der Gugten J, Olivier B. Light-enhanced and fear-potentiated startle: temporal characteristics and effects of a-helical corticotropin-releasing hormone, 1041
de Wit J. *See* Eisch AJ
Dean B. *See* Thomas EA
Dean B, Laws SM, Hone E, Taddei K, Scarr E, Thomas EA, Harper C, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia, 616
Degen K. *See* Kugaya A
Del-Favero J. *See* Claes S
DeLong MR. *See* McDonald WM
DePaulo JR Jr. *See* McInnis MG
Depner M. *See* Schumann G
Detera-Wadleight SD. *See* McInnis MG
Devlin MJ. *See* Walsh BT
Di Salle F. *See* Seifritz E
Dick DM. *See* McInnis MG
Diggs T. *See* McInnis MG
Dimoska A, Johnstone SJ, Barry RJ, Clarke AR. Inhibitory motor control in children with attention-deficit/hyperactivity disorder: event-related potentials in the stop-signal paradigm, 1345
Doku V. *See* Fannon D
Donegan NH, Sanislow CA, Blumberg HP, Fulbright RK, Lacadie C, Skudlarski P, Gore JC, Olson IR, McGlashan TH, Wexler BE. Amygdala hyperreactivity in

borderline personality disorder: implications for emotional dysregulation, 1284
Doudet DJ, Holden JE. Raclopride studies of dopamine release: dependence on presynaptic integrity, 1193
Douglas SD. *See* Cruess DG
Dowson JH. *See* Aron AR
Doyle R. *See* Wilens TE
Drevets WC. *See* Phillips ML
Drewe J. *See* Stoermer R
Ducrocq F. *See* Vaiva G
Duman RS. *See* Cavus I; Madsen TM; Sheehan TP; Tolbert LM
Dunner DL. *See* Gelenberg AJ
During MJ. *See* Haile CN
Dursteler-Mac Farland KM. *See* Stoermer R

Eaton ME. *See* Madsen TM
Ebert D. *See* van Elst LT
Eberwine JH. *See* Hinkle DA
Edenberg HJ. *See* McInnis MG
Edwards ER. *See* Yaffe K
Egan MF. *See* Winterer G
Ehlert U. *See* Heinrichs M
Eichhammer P, Langguth B, Marienhagen J, Kleinjung T, Hajak G. Neuronavigated repetitive transcranial magnetic stimulation in patients with tinnitus: a short case series, 862
Eisch AJ, Bolaños CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, Verhaagen J, Nestler EJ. Brain-derived neurotrophic factor in the ventral midbrain–nucleus accumbens pathway: a role in depression, 994
Ekdahl CT. *See* Wennström M
Elzinga BM. *See* Schmahl CG
Emilsson L. *See* Castensson A
Eravci M. *See* Pinna G
Eronen M. *See* Tiihonen J
Esposito F. *See* Seifritz E
Evans DL. *See* Cruess DG
Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem, 177=ed

Fadale D. *See* Levitt JG
Fahey JL. *See* Cole SW
Faith MS. *See* Stunkard AJ
Falkai P. *See* Tepest R
Fannon D, Simmons A, Tennakoon L, O'Céallaigh S, Sumich A, Doku V, Shew C, Sharm T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia, 587
Faraone SV. *See* Glatt SJ; Takahashi S
Fava M. *See* Perlis RH
Fenton W. *See* Stover E
Ferrell RE. *See* Yaffe K
Ferro EF. *See* Gallinat J
Ferrucci L. *See* Penninx BWJH
Fletcher JM. *See* Shaywitz SE
Foroud TM. *See* McInnis MG
Forsgren T. *See* Claes S
Fox NA. *See* Bar-Haim Y
Francis JH. *See* Lira A
Frank E. *See* Brambilla P
Frederick B. *See* Kaufman MJ
Freedland KE. *See* Carney RM
Freedman N. *See* Bonne O
Frumin M. *See* Kubicki M
Fuchs D. *See* Capuron L
Fuchs E. *See* Coe CL
Fujimaki K. *See* Morinobu S
Fujita M. *See* Kugaya A
Fulbright RK. *See* Donegan NH; Shaywitz SE
Furac I. *See* Hranilovic D
Fuxius S. *See* Pinna G

Gallinat J. *See* Wernicke C
Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, Goldman D, Winterer G. Association of the G1947A COMT (Val108/158Met) gene polymorphism with prefrontal P300 during information processing, 40
Gandy SE. *See* Dean B; Thomas EA
Gangadhar BN. *See* Jayakumar PN
Gass P. *See* Vollmayr B; Zörner B
Geiger E. *See* van Elst LT
Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RMA, Keitner GI, Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnow B, Rothbaum B, Munsaka M, Banks P, Borian FE, Keller MB. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression, 806
Germain A, Nielsen TA. Sleep pathophysiology in posttraumatic stress disorder and idiopathic nightmare sufferers, 1092
Gershon ES. *See* McInnis MG
Gettes D. *See* Cruess DG
Geyer MA. *See* Ludewig K
Gialloreti LE. *See* Tecchio F
Giampietro V. *See* Kumari V
Gibson KM, Gupta M, Pearl PL, Tuchman M, Vezina LG, Snead OC III, Smit LME, Jakobs C. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria), 763
Giegling I. *See* Rujescu D; Schumann G
Giese-Davis J. *See* Spiegel D
Gietl A. *See* Rujescu D
Gilboa A. *See* Bonne O
Gingrich JA. *See* Lira A
Girard K. *See* Wilens TE
Glatt SJ, Faraone SV, Tsuang MT. Schizophrenia is not associated with DRD4 48-base-pair-repeat length of individual alleles: results of a meta-analysis, 629
Goate AM. *See* McInnis MG
Gold PW. *See* Contoreggi C
Goldapple K. *See* Krüger S
Goldberg S, Levitan R, Leung E, Masellis M, Basile VS, Nemeroff CB, Atkinson L. Cortisol concentrations in 12- to 18-month-old infants: stability over time, location, and stressor, 719
Goldberg TE. *See* Winterer G
Goldman D. *See* Gallinat J
Goldman S. *See* Wilens TE
Goldman-Rakic PS. *See* Castner SA
Goodman WK. *See* Shapira NA
Gordon JA. *See* Lira A
Gordon-Salant S. *See* Bar-Haim Y
Gore JC. *See* Donegan NH; Shaywitz SE
Goren J. *See* Silveri MM
Gorman JM. *See* Mathew SJ
Gould E. *See* Coe CL
Grasby PM. *See* Bhagwagar Z
Grauer MT. *See* Uhr M
Green A. *See* Potkin SG
Groenink L. *See* de Jongh R
Grunwald I. *See* Zörner B
Gunawardene s. *See* Wilens TE
Gupta M. *See* Gibson KM
Gur RC. *See* Ragland JD
Gur RE. *See* Ragland JD
Guss J. *See* Walsh BT
Guthrie D. *See* Levitt JG
Gutierrez O. *See* Valdizán EM

Haegele K. *See* van Elst LT

Hagino H. *See* Zhou S-Y
Haile CN, During MJ, Jatlow PI, Kosten TR, Kosten TA. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats, 915
Hajak G. *See* Eichhammer P; Müller JL
Hallikainen T. *See* Tiihonen J
Hamann C. *See* Pogarell O
Hammerness P. *See* Wilens TE
Han Y. *See* Yang J
Han Y-H. *See* Takahashi S
Haroutunian VH. *See* Martin-Ruiz CM
Harper C. *See* Dean B; Thomas EA
Harris T. *See* Penninx BWJH
Hartmann AM. *See* Rujescu D
Harvey BH, McEwen BS, Stein DJ. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression, 1105
Hashimoto K. *See* Nakazato M; Shimizu E
Hauger RL. *See* Kühlwein E; Morgan CA III
Haukka J. *See* Kieseppä T; Tuulio-Henriksson A
Hawkins KA. *See* Woods SW
Hazlett G. *See* Morgan CA III
He AG. *See* Shapira NA
Hegerl U. *See* Pogarell O
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress, 1389
Heitz M-P. *See* Le Pen G
Hellsten J. *See* Wennström M
Hen R. *See* Lira A
Heninger G. *See* Bremner JD
Henn F. *See* Vollmayr B
Henn FA. *See* Schumann G; Zörner B
Hennen J. *See* Kaufman MJ
Henning J. *See* van Elst LT
Henry ME. *See* Kaufman MJ
Herning RI. *See* Contoreggi C
Herscovitch P. *See* Speer AM
Hesslinger B. *See* van Elst LT
Hietala J. *See* Joyal CC
Hill SK. *See* Ragland JD
Hinkle DA, Eberwine JH. Single-cell molecular biology: implications for diagnosis and treatment of neurologic disease, 413
Hirschfeld RMA. *See* Gelenberg AJ
Hirshfeld-Becker D. *See* Smoller JW
Ho B-C. *See* Milev P
Hock C. *See* Stoermer R
Hofer MA. *See* Lira A
Holahan JM. *See* Shaywitz SE
Holden JE. *See* Doudet DJ
Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression, 953
Holsboer F. *See* Uhr M
Hone E. *See* Dean B
Horodnicki J. *See* Wernicke C
Howland R. *See* Gelenberg AJ
Hoyer D. *See* Cryan JF
Hranilovic D, Stefulj J, Furac I, Kubat M, Balija M, Jernej B. Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms in Croatian suicide victims, 884
Hsu C. *See* Potkin SG
Huang HY. *See* Simpson HB
Huo Y. *See* McInnis MG
Huttunen MO. *See* Johnson JK
Hwang D-R. *See* Simpson HB
Hybels CF. *See* Steffens DC
Hyman SE. Methylphenidate-induced plasticity: what should we be looking for?, 1310=ED

Ibrahim HM. *See* Rush AJ
Inagaki M. *See* Matusoka Y
Ingjaldssoon JT, Laberg JC, Thayer JF. Reduced heart rate variability in chronic alcohol abuse: relationship with negative mood, chronic thought suppression, and compulsive drinking, 1427
Innis RB. *See* Kugaya A
Insel TR. *See* Stover E; Volkow ND
Irizarry K. *See* Lee CJ
Irwin MR. *See* Kühlwein E
Ivey J. *See* Smith EA
Iyo M. *See* Nakazato M; Shimizu E

Jakobs C. *See* Gibson KM
James GA. *See* Shapira NA
Janakiramaiah N. *See* Jayakumar PN
Jatlow PI. *See* Haile CN
Jayakumar PN, Gangadhar BN, Subbakrishna DK, Janakiramaiah N, Srinivas JS, Keshavan MS. Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia: a 31P magnetic resonance spectroscopy study, 491
Jazin E. *See* Castensson A
Jernej B. *See* Hranilovic D
Jezequel K. *See* Vaiva G
Johnson B. *See* Salomon RM
Johnson JE. *See* Sautter FJ
Johnson JK, Tuulio-Henriksson A, Pirkola T, Huttunen MO, Lönnquvist J, Kaprio J, Cannon TD. Do schizotypal symptoms mediate the relationship between genetic risk for schizophrenia and impaired neuropsychological performance in co-twins of schizophrenic patients?, 1200
Johnson MH. Development of human brain functions, 1312
Johnston P. *See* Stojanov W
Johnstone SJ. *See* Dimoska A
Jolesz FA. *See* Kubicki M
Jones H. Regarding "chaos and schizophrenia: does the method fit the madness?", 661=corr
Joyal CC, Laakso MP, Tiihonen J, Syvälahti E, Vilkman H, Laakso A, Alakare B, Räkköläinen V, Salokangas RKR, Hietala J. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients, 1302
Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction, 248
Juckel G. *See* Pogarell O

Kagan J. *See* Smoller JW
Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment, 388
Kaplan Z. *See* Weiser M
Kaprio J. *See* Johnson JK
Karayanidis F. *See* Stojanov W
Kasper S. *See* Willeit M
Kato N. *See* Morinobu S
Kaufman MJ, Henry ME, Frederick B, Hennen J, Villafuerte RA, Stoddard EP, Schmidt ME, Cohen BM, Renshaw PF. Selective serotonin reuptake inhibitor discontinuation is associated with a rostral anterior cingulate metabolite decrease: a proton magnetic resonance spectroscopic imaging study, 534
Kaufmann PG. Depression in cardiovascular disease: can the risk be reduced?, 187=comm

Kawano K-i. *See* Morinobu S
Kawasaki Y. *See* Zhou S-Y
Keefe FJ. *See* Campbell LC
Kegeles LS. *See* Mathew SJ
Keitner GI. *See* Gelenberg AJ
Kellendonk C. *See* Morozov A
Keller MB. *See* Gelenberg AJ; Rush AJ
Kelly L. *See* Vythilingam M
Kelser SR, Blasey CM, Brown WE, Yankowitz J, Zeng SM, Bender BG, Reiss AL. Effects of X-monosomy and X-linked imprinting on superior temporal gyrus morphology in Turner syndrome, 636
Kemeny ME. *See* Cole SW
Kempermann G, Kronenberg G. Depressed new neuronsemdashadult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression, 499
Kennedy J. *See* Smoller JW
Kennedy JS. *See* Salomon RM
Kennedy SH. *See* Krüger S
Keshavan MS. *See* Brambilla P; Jayakumar PN
Kew J. *See* Le Pen G
Khan SA. *See* Kugaya A
Kieseppä T, van Erp TGM, Haukka J, Partonen T, Cannon TD, Poutanen V-P, Kaprio J, Lönnqvist J. Reduced left hemispheric white matter volume in twins with bipolar I disorder, 896
Kikinis R. *See* Kubicki M
Kim KJ, Peterson BS. Cavum septi pellucidi in Tourette syndrome, 76
Kirschbaum C. *See* Coe CL; Heinrichs M
Kissileff HR. *See* Walsh BT
Kissling C. *See* Schumann G
Klein DN. *See* Gelenberg AJ; Rush AJ
Klein HE. *See* Müller JL
Klein R. *See* Zörner B
Kleinjung T. *See* Eichhammer P
Knobler HY. *See* Weiser M
Kocsis JH. *See* Gelenberg AJ; Rush AJ
Koike K. *See* Shimizu E
Koizumi H. *See* Nakazato M
Kojima T. *See* Takahashi S
Komatsu N. *See* Nakazato M; Shimizu E
Kong Q. *See* Yang J
Kornstein S. *See* Rush AJ
Kornstein SG. *See* Gelenberg AJ
Kosten TA. *See* Haile CN
Kosten TR. *See* Haile CN
Kotilainen I. *See* Tiihonen J
Kramer M. *See* Coe CL
Kremer C. *See* Murphy GM Jr
Kretz O. *See* Zörner B
Krishan KRR. *See* Lee S-H; Potkin SG; Vythilingam M
Kritchevsky SB. *See* Penninx BWJH
Kronenberg G. *See* Kempermann G
Krüger S, Seminowicz D, Goldapple K, Kennedy SH, Mayberg HS. State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge, 1274
Kruyt ND. *See* Sandi C
Kubat M. *See* Hranilovic D
Kubicki M, Westin C-F, Nestor PG, Wible CG, Frumin M, Maier SE, Kikinis R, Jolesz FA, McCarley RW, Shenton ME. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study, 1171
Kucharska-Mazur J. *See* Wernicke C
Kugaya A, Sanacora G, Verhoeff NPLG, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT, 792
Kühlwein E, Hauger RL, Irwin MR. Abnormal nocturnal melatonin secretion and disordered sleep in abstinent alcoholics, 1437
Kumakiri C. *See* Nakazato M; Shimizu E
Kumari V, Mitterschiffthaler MT, Teasdale JD, Malhi GS, Brown RG, Giampietro V, Brammer MJ, Poon L, Simmons A, Williams SCR, Checkley SA, Sharma T. Neural abnormalities during cognitive generation of affect in treatment-resistant depression, 777
Kung HF. *See* Lira A
Kupfer DJ. *See* Brambilla P
Kurachi M. *See* Zhou S-Y

Laakso A. *See* Joyal CC
Laakso MP. *See* Joyal CC
Laberg JC. *See* Ingjaldssoon JT
Lacadie C. *See* Donegan NH
Ladewig D. *See* Stoermer R
Lai T-J. *See* Lee S-H
Laird NM. *See* Smoller JW
Lamon-Fava S. *See* Perlis RH
Lane R. *See* Phillips ML
Lang PJ. *See* Shapira NA
Lange K. *See* Müller JL
Langguth B. *See* Eichhammer P
Langstrom B. *See* Learned-Coughlin SM
Larsen H. *See* Musselman DL
Laruelle M. *See* Simpson HB
Lascorz J. *See* Schumann G
Lautenschlager N. *See* Dean B; Thomas EA
Laws SM. *See* Dean B; Thomas EA
Lawson DH. *See* Capuron L
Le Pen G, Kew J, Alberati D, Borroni E, Heitz M-P, Moreau J-L. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal–lesioned rats: reversal by glycine and a glycine transporter inhibitor, 1162
Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography, 800
Lee CJ, Irizarry K. Alternative splicing in the nervous system: an emerging source of diversity and regulation, 771
Lee HB, Lyketsos CG. Depression in Alzheimer's disease: heterogeneity and related issues, 353
Lee S-H, Payne ME, Steffens DC, McQuoid DR, Lai T-J, Provenzale JM, Krishan KRR. Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression, 529
Lemieux L. *See* van Elst LT
Lenoci M. *See* Neylan TC
Leserman J. HIV disease progression: depression, stress, and possible mechanisms, 295
Lessig MC. *See* Shapira NA
Lestavel P. *See* Vaiva G
Lester H. *See* Bonne O
Leung E. *See* Goldberg S
Levac C. *See* Merali Z
Levitan R. *See* Goldberg S
Levitt JG, O'Neill J, Blanton RE, Smalley S, Fadale D, McCracken JT, Guthrie D, Toga AW, Alger JR. Proton magnetic resonance spectroscopic imaging of the brain in childhood autism, 1355
Lewis DA. *See* Pierri JN

Lewis L. Recognizing and meeting the needs of patients with mood disorders and comorbid medical illness: a consensus conference of the Depression and Bipolar Support Alliance, 181=comm
Li X. *See* Yang J
Lieb K. *See* van Elst LT
Liebowitz MR. *See* Simpson HB
Lin K-M. *See* Perlis RH
Lindborg SR. *See* Woods SW
Ling Y. *See* Yang J
Lipp H-P. *See* Zörner B
Lira A, Zhou M, Castanon N, Ansorge MS, Gordon JA, Francis JH, Bradley-Moore M, Lira J, Underwood MD, Arango V, Kung HF, Hofer MA, Hen R, Gingrich JA. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice, 960
Lira J. *See* Lira A
Lisanby SH. *See* Mathew SJ
Liu C. *See* Yang J
Liu S. *See* Yang J
Liu Y. *See* Shapira NA
Lombardo I. *See* Simpson HB
Long P. *See* Martin-Ruiz CM
Lönnqvist J. *See* Johnson JK; Kieseppä T; Tuulio-Henriksson A
Lorch E. *See* Smith EA
Lorenzi C. *See* Benedetti F
Louzoun Y. *See* Bonne O
Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia, 121
Lui L-Y. *See* Yaffe K
Lüthi A. *See* Seifritz E
Lyketsos CG. *See* Lee HB
Lyon GR. *See* Shaywitz SE

Ma D. *See* Yang J
MacFall JR. *See* Steffens DC
MacKinnon DF. *See* McInnis MG
Madani R. *See* Zörner B
Madsen TM. *See* Altar CA
Madsen TM, Newton SS, Eaton ME, Russell DS, Duman RS. Chronic electroconvulsive seizure up-regulates b-catenin expression in rat hippocampus: role in adult neurogenesis, 1006
Mager R. *See* Stoermer R
Magnotta V. *See* White T
Mague SD. *See* Carlezon WA Jr
Mahendran R. *See* Tan E-C
Maier SE. *See* Kubicki M
Malaspina D. *See* Sautter FJ
Malhi GS. *See* Kumari V
Mallinger AG. *See* Brambilla P
Manber R. *See* Gelenberg AJ; Rush AJ
Manguno-Mire G. *See* Sautter FJ
Mann K. *See* Schumann G
Mao X. *See* Mathew SJ
Marchione KE. *See* Shaywitz SE
Marienhagen J. *See* Eichhammer P
Marinelli M. *See* Brandon CL
Mark M. *See* Weiser M
Markou A. *See* Cryan JF; Semenova S
Markowitz JC. *See* Gelenberg AJ; Rush AJ
Marmar CR. *See* Neylan TC; Vaiva G
Marquez E. *See* Woods SW
Marshall PJ. *See* Bar-Haim Y
Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, Court JA. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia, 1222
Martins RN. *See* Dean B; Thomas EA
Martis B. *See* Wright CI
Masellis M. *See* Goldberg S
Mason GF. *See* Kugaya A
Masters C. *See* Dean B; Thomas EA
Mathew SJ, Shungu DC, Mao X, Smith ELP, Perera GM, Kegeles LS, Perera T, Lisanby SH, Rosenblum LA, Gorman JM, Coplan JD. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors, 727
Matsushima E. *See* Takahashi S
Matsuura M. *See* Takahashi S
Matteini AT. *See* McInnis MG
Matusoka Y, Yamawaki S, Inagaki M, Akechi T, Uchitomi Y. A volumetric study of amygdala in cancer survivors with intrusive recollections, 736
Mayberg HS. *See* Krüger S
McCarley RW. *See* Kubicki M
McClean C. *See* Dean B; Thomas EA
McCracken JT. *See* Levitt JG
McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease, 363
McEwen BS. *See* Harvey BH
McEwen BS. Mood disorders and allostatic load, 200
McGlashan TH. *See* Bremner JD; Donegan NH; Schmahl CG; Woods SW
McGrath C. *See* Ragland JD
McInnis MG, Dick DM, Willour VL, Avramopoulos D, MacKinnon DF, Simpson SG, Potash JB, Edenberg HJ, Bowman ES, McMahon FJ, Smiley C, Chellis JL, Huo Y, Diggs T, Meyer ET, Miller M, Matteini AT, Rau L, Depaulo JR Jr, Gershon ES, Badner JA, Rice JP, Goate AM, Detera-Wadleight SD, Nurnberger JI Jr, Reich T, Zandi PP, Foroud TM. Genome-wide scan and conditional analysis in bipolar disorder: evidence for genomic interaction in the National Institute of Mental Health Genetics Initiative Bipolar Pedigrees, 1265
McMahon FJ. *See* McInnis MG
McMullin K. *See* Wright CI
McQuoid DR. *See* Lee S-H
Meinhold H. *See* Pinna G
Meltzer H. *See* Potkin SG
Mencl WE. *See* Shaywitz SE
Merali Z, Levac C, Anisman H. Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice, 552
Merino JJ. *See* Sandi C
Meyer ET. *See* McInnis MG
Mignot E. *See* Salomon RM
Milev P, Ho B-C, Arndt S, Nopoulos P, Andreasen NC. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up, 608
Miller AH. *See* Capuron L; Raison CL
Miller I. *See* Gelenberg AJ
Miller M. *See* McInnis MG
Miller MI. *See* Tepest R
Miller TJ. *See* Woods SW
Mischoulon D. *See* Perlis RH
Mistretta P. *See* Cavallaro R
Mitsumori M. *See* Nakazato M
Mitterschiffthaler MT. *See* Kumari V
Moelter ST. *See* Ragland JD
Möller H-J. *See* Pogarell O; Rujescu D
Montgomery AJ. *See* Bhagwagar Z
Monuteaux M. *See* Wilens TE
Moore GJ. *See* Smith EA
Moreau J-L. *See* Le Pen G
Morgan CA III, Rasmusson AM, Winters B, Hauger RL, Morgan J, Hazlett

G, Southwick S. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels, 1087
Morgan J. *See* Morgan CA III
Morinobu S, Fujimaki K, Kawano K-i, Tanaka K, Takahashi J, Ohkawa M, Yamawaki S, Kato N. Influence of immobilization stress on the expression and phosphatase actiuvity of protein phosphatase 2A in the rat brain, 1060
Morozov A, Kellendonk C, Simpson E, Tronche F. Using conditional mutagenesis to study the brain, 1125
Mueller-Spahn F. *See* Stoermer R
Müller JL, Sommer M, Wagner V, Lange K, Taschler H, Röder CH, Schuierer G, Klein HE, Hajak G. Abnormalities in emotion processing within cortical and subcortical regions in criminal psychopaths: evidence from a functional magnetic resonance imaging study using pictures using emotional content, 152
Munsaka M. *See* Gelenberg AJ
Murphy DL. *See* Holmes A
Murphy GM Jr, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively impact elderly depressed patients, 665
Murphy KJ. *See* Sandi C
Murphy T. *See* Uher R
Musselman DL. *See* Capuron L
Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes type 1 and 2: epidemiology, biology, and treatment, 317
Mustovic H. *See* Seifritz E
Myers L. *See* Sautter FJ

Na P. *See* Contoreggi C
Nahon D. *See* Weiser M
Nakayama J. *See* Takahashi S
Nakazato M. *See* Shimizu E
Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N, Mitsumori M, Komatsu N, Iyo M. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders, 485
Naliboff BD. *See* Cole SW
Negro PJ. *See* Contoreggi C
Nemeroff CB. *See* Capuron L; Goldberg S; Rudisch B
Nestler EJ. *See* Bolaños CA; Eisch AJ
Nestor PG. *See* Kubicki M
Neuhoff JG. *See* Seifritz E
Neumeister A. *See* Willeit M
Neurauter G. *See* Capuron L
Neve RL. *See* Sheehan TP
Newman AB. *See* Penninx BWJH
Newton SS. *See* Madsen TM
Neylan TC, Schuff N, Lenoci M, Yehuda R, Weiner MW, Marmar CR. Cortisol levels are positively correlated with hippocampal N-acetylaspartate, 1118
Ng VW. *See* Uher R
Nicoletti MA. *See* Brambilla P
Nielsen TA. *See* Germain A
Ninan PT. *See* Rush AJ
Nishino S. *See* Salomon RM
Nishino S. The hypocretin/orexin system in health and disease, 87
Nohara S. *See* Zhou S-Y
Nopoulos P. *See* Milev P; White T
Nurnberger JI Jr. *See* McInnis MG

O'Céallaigh S. *See* Fannon D
O'Connor CM. *See* Joynt KE
Ohkawa M. *See* Morinobu S
Okada S-i. *See* Shimizu E
Okamura N. *See* Nakazato M; Shimizu E
Olivier B. *See* de Jongh R
Olson IR. *See* Donegan NH
O'Neill HC, Schmitt MP, Stevens KE. Lithium alters measures of auditory gating in two strains of mice, 847
O'Neill J. *See* Levitt JG

Pahor M. *See* Penninx BWJH
Palermo M. *See* Tecchio F
Parow AM. *See* Silveri MM
Partonen T. *See* Kieseppä T; Tuulio-Henriksson A
Payne ME. *See* Lee S-H; Steffens DC
Pazos A. *See* Valdizán EM
Pearl PL. *See* Gibson KM
Peng K. *See* Tan E-C
Penninx BWJH, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L, Harris T, Pahor M. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study, 566
Perera GM. *See* Mathew SJ
Perera T. *See* Mathew SJ
Perkins DO. *See* Woods SW
Perlis RH, Mischoulon D, Smoller JW, Wan Y-J Y, Lamon-Fava S, Lin K-M, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment, 879
Perry EK. *See* Martin-Ruiz CM
Peterson BS. *See* Kim KJ
Petitto JM. *See* Cruess DG
Phillips LS. *See* Musselman DL
Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: the neural basis of normal emotion perception, 504
Pierri JN, Volk CLE, Auh S, Sampson A, Lewis DA. Somal size of prefrontal cortical pyramidal neurons in schizophrenia: differential effects across neuronal subpopulations, 111
Pinna G, Broedel O, Eravci M, Stoltenburg-Didinger G, Plueckhan H, Fuxius S, Meinhold H, Baumgartner A. Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation, 1049
Pirkola T. *See* Johnson JK
Plueckhan H. *See* Pinna G
Pogarell O, Hamann C, Pöpperl G, Juckel G, Choukèr M, Zaudig M, Riedel M, Möller H-J, Hegerl U, Tatsch K. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder, 1406
Pontiggia A. *See* Benedetti F
Poon L. *See* Kumari V
Pöpperl G. *See* Pogarell O
Post RM. *See* Speer AM
Potash JB. *See* McInnis MG
Potkin SG, Alphs L, Hsu C, Krishan KRR, Anand R, Young FK, Meltzer H, Green A. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial, 444
Poustka A. *See* Schumann G
Poutanen V-P. *See* Kieseppä T
Praschak-Rieder N. *See* Willeit M
Preuss UW. *See* Schumann G
Prince JB. *See* Wilens TE
Provenzale JM. *See* Lee S-H
Pudiak CM. *See* Eisch AJ

Pugh KR. *See* Shaywitz SE
Putkonen A. *See* Tiihonen J

Rabinowitz J. *See* Weiser M
Racette SR. *See* Smoller JW
Radue EW. *See* Seifritz E
Ragland JD, Moelter ST, McGrath C, Hill SK, Gur RE, Bilker WB, Siegel SJ, Gur RC. Levels-of-processing effect on word recognition in schizophrenia, 1154
Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment, 283
Räkköläinen V. *See* Joyal CC
Rasmusson A. *See* Bremner JD
Rasmusson AM. *See* Morgan CA III
Rau NL. *See* McInnis MG
Rauch SL. *See* Phillips ML; Wright CI
Reeves AJ. *See* Coe CL
Regan CM. *See* Sandi C
Reich T. *See* McInnis MG
Reichenberg A. *See* Weiser M
Reiss AL. *See* Kelser SR
Reite M. *See* Teale P
Renshaw PF. *See* Kaufman MJ; Silveri MM
Repetto MJ. *See* Cruess DG
Repo-Tiihonen E. *See* Tiihonen J
Rice JP. *See* McInnis MG
Richard IH. *See* McDonald WM
Riedel M. *See* Pogarell O
Ripley B. *See* Salomon RM
Robbins TW. *See* Aron AR
Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression, 376
Röder CH. *See* Müller JL
Rodrigues H. *See* Murphy GM Jr
Rojas D. *See* Teale P
Rommelspacher H. *See* Wernicke C
Roose SP. Treatment of depression in patients with heart disease, 262
Rose M. *See* Smith EA
Rosenbaum JF. *See* Perlis RH; Smoller JW
Rosenberg DR. *See* Smith EA
Rosenblum LA. *See* Mathew SJ
Rosenfeld A. *See* Stover E
Rossini PM. *See* Tecchio F
Rothbaum B. *See* Gelenberg AJ
Rowland JH. *See* Croyle RT
Ruan Y. *See* Yang J
Rubin S. *See* Penninx BWJH
Rubinow DR. *See* Smith MJ
Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression, 227
Rujescu D. *See* Schumann G
Rujescu D, Giegling I, Gietl A, Hartmann AM, Möller H-J. A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits, 34
Rujescu D, Giegling I, Sato T, Hartmann AM, Möller H-J. Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis, 465
Rush AJ. *See* Gelenberg AJ
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression, 573
Russell A. *See* Smith EA
Russell DS. *See* Madsen TM; Sheehan TP; Tolbert LM
Russell JM. *See* Gelenberg AJ
Ryynänen O-P. *See* Tiihonen J

Sahakian BJ. *See* Aron AR
Salkangas RKR. *See* Joyal CC
Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects, 96
Samochowiec J. *See* Wernicke C
Sampson A. *See* Pierri JN
Sanacora G. *See* Kugaya A
Sander T. *See* Gallinat J
Sandi C, Merino JJ, Cordero I, Kruyt ND, Murphy KJ, Regan CM. Modulation of hippocampal NCAM polysialylation and spatial memory consolidation by fear conditioning, 599
Sanislow CA. *See* Donegan NH; Schmahl CG
Sassi RB. *See* Brambilla P
Sato T. *See* Rujescu D
Sautter FJ, Bissette G, Wiley J, Manguno-Mire G, Schoenbachler B, Myers L, Johnson JE, Cerbone A, Malaspina D. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects, 1382
Savitcheva I. *See* Learned-Coughlin SM
Scarr E. *See* Dean B
Schall U. *See* Stojanov W
Schatzberg AF. *See* Murphy GM Jr
Schlattmann P. *See* Gallinat J
Schmahl CG, Elzinga BM, Vermetten E, Sanislow C, McGlashan TH, Bremner JD. Neural correlates of memories of abandonment in women with and without borderline personality disorder, 142
Schmidt D. *See* Salomon RM
Schmidt LG. *See* Wernicke C
Schmidt ME. *See* Kaufman MJ
Schmidt PJ. *See* Smith MJ
Schmith VD. *See* Learned-Coughlin SM
Schmitt MP. *See* O'Neill HC
Schoenbachler B. *See* Sautter FJ
Schorr EA. *See* Bar-Haim Y
Schrek M. *See* Tuulio-Henriksson A
Schuff N. *See* Neylan TC
Schuierer G. *See* Müller JL
Schumann G, Rujescu D, Kissling C, Soyka M, Dahmen N, Preuss UW, Wieman S, Depner M, Wellek S, Lascorz J, Bondy B, Giegling I, Anghelescu I, Cowen MS, Poustka A, Spanagel R, Mann K, Henn FA, Szegedi A. Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts, 1422
Seibyl JP. *See* Kugaya A
Seifritz E, Esposito F, Neuhoff JG, Lüthi A, Mustovic H, Dammann G, von Bardeleben U, Radue EW, Cirillo S, Tedeschi G, Di Salle F. Differential sex-independent amygdala response to infant crying and laughing in parents versus nonparents, 1367
Semenova S, Markou A. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subset of rats exhibiting hyposensitivity to the initial effects of clozapine, 1249
Seminowicz D. *See* Krüger S
Seneca NM. *See* Kugaya A

Seri S. *See* Tecchio F
Serretti A. *See* Benedetti F
Seto H. *See* Zhou S-Y
Shalev AY. *See* Bonne O
Shapira NA, Liu Y, He AG, Bradley MM, Lessig MC, James GA, Stein DJ, Lang PJ, Goodman WK. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder, 751
Sharm T. *See* Fannon D
Sharma T. *See* Kumari V
Shaywitz BA. *See* Shaywitz SE
Shaywitz SE, Shaywitz BA, Fulbright RK, Skudlarski P, Mencl WE, Constable RT, Pugh KR, Holahan JM, Marchione KE, Fletcher JM, Lyon GR, Gore JC. Neural systems for compensation and persistence: young adult outcome of childhood reading disability, 25
Sheehan TP, Neve RL, Duman RS, Russell DS. Antidepressant effect of the calcium-activated tyrosine kinase Pyk2 in the lateral septum, 540
Sheline YI. Neuroimaging studies of mood disorder effects on the brain, 338
Shelton JR. *See* Speer AM
Shen Y-C. *See* Takahashi S
Shenton ME. *See* Kubicki M
Shew C. *See* Fannon D
Shimizu E. *See* Nakazato M
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S-i, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants, 70
Shin LM. *See* Wright CI
Shinoda N. *See* Shimizu E
Shu L. *See* Yang J
Shungu DC. *See* Mathew SJ
Si T. *See* Yang J
Siegel SJ. *See* Ragland JD
Siegle GJ. *See* Condray R
Silveri MM, Parow AM, Villafuerte RA, Damico KE, Goren J, Stoll AL, Cohen BM, Renshaw PF. S-Adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects, 833
Simmons A. *See* Fannon D; Kumari V
Simon GE. Social and economic burden of mood disorders, 208
Simonak RD. *See* Eisch AJ
Simonis C. *See* Vollmayr B
Simonsick EM. *See* Penninx BWJH
Simpson E. *See* Morozov A
Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang D-R, Abi-Dargham A, Liebowitz MR, Laruelle M. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652, 1414
Simpson SG. *See* McInnis MG
Sklar PB. *See* Smoller JW
Skudlarski P. *See* Donegan NH; Shaywitz SE
Slaugenhaupt SA. *See* Smoller JW
Slifstein M. *See* Simpson HB
Sluijs S. *See* Claes S
Smalley S. *See* Levitt JG
Smeraldi E. *See* Benedetti F
Smiley C. *See* McInnis MG
Smit LME. *See* Gibson KM
Smith EA, Russell A, Lorch E, Banerjee SP, Rose M, Ivey J, Bhandari R, Moore GJ, Rosenberg DR. Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study, 1399
Smith ELP. *See* Mathew SJ
Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome, 757
Smolka M. *See* Wernicke C
Smoller JW. *See* Perlis RH
Smoller JW, Rosenbaum JF, Biederman J, Kennedy J, Dai D, Racette SR, Laird NM, Kagan J, Snidman N, Hirshfeld-Becker D, Tsuang MT, Sklar PB, Slaugenhaupt SA. Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition, 1376
Snead OC III. *See* Gibson KM
Snidman N. *See* Smoller JW
Soares JC. *See* Brambilla P
Sommer M. *See* Müller JL
Southwick S. *See* Morgan CA III
Southwick SM. *See* Bremner JD; Vermetten E
Soyka M. *See* Schumann G
Spanagel R. *See* Schumann G
Speer AM, Willis MW, Herscovitch P, Daube-Witherspoon M, Shelton JR, Benson BE, Post RM, Wassermann EM. Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: I. Effects of primary motor cortex rTMS, 818
Spencer T. *See* Wilens TE
Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression, 269
Srinivas JS. *See* Jayakumar PN
Steffens DC. *See* Lee S-H
Steffens DC, Trost WT, Payne ME, Hybels CF, MacFall JR. Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects, 674
Stefulj J. *See* Hranilovic D
Stein DJ. *See* Harvey BH; Shapira NA
Steinhauer SR. *See* Condray R
Stevens KE. *See* O'Neill HC
Stoddard EP. *See* Kaufman MJ
Stoermer R, Drewe J, Dursteler-Mac Farland KM, Hock C, Mueller-Spahn F, Ladewig D, Stohler R, Mager R. Safety of injectable opioid maintenance treatment for heroin dependence, 854
Stohler R. *See* Stoermer R
Stojanov W, Karayanidis F, Johnston P, Bailey A, Carr V, Schall U. Disrupted sensory gating in pathological gambling, 474
Stoll AL. *See* Silveri MM
Stoltenburg-Didinger G. *See* Pinna G
Stover E, Fenton W, Rosenfeld A, Insel TR. Depression and comorbid medical illness: the National Institute of Mental Health perspective, 184=comm
Stunkard AJ, Faith MS, Allison KC. Depression and obesity, 330
Subbakrishna DK. *See* Jayakumar PN
Sumich A. *See* Fannon D
Sundberg R. *See* Castensson A
Sutcliffe JG. *See* Thomas EA
Suzuki M. *See* Zhou S-Y
Syvälahti E. *See* Joyal CC
Szegedi A. *See* Schumann G

Taddei K. *See* Dean B
Takahashi J. *See* Morinobu S
Takahashi S, Cui Y-H, Kojima T, Han Y-H, Yu S-Y, Tanabe E, Yara K, Matsuura M, Matsushima E, Nakayama J, Arinami T, Shen Y-C, Faraone SV, Tsuang MT. Family-based association study of the NOTCH4 gene in schizophrenia using Japanese and Chinese samples, 129
Takahashi T. *See* Zhou S-Y
Tan C-H. *See* Tan E-C
Tan E-C, Chong S-A, Tan C-H, Teo Y-Y, Peng K, Mahendran R. Tumor necrosis factor-a gene promoter polymorphisms in chronic schizophrenia, 1205
Tanabe E. *See* Takahashi S
Tanaka K. *See* Morinobu S
Taschler H. *See* Müller JL
Tatsch K. *See* Pogarell O
Teale P, Carlson J, Rojas D, Reite M. Reduced laterality of the source locations for generators of the auditory steady-state field in schizophrenia, 1149
Teasdale JD. *See* Kumari V
Tecchio F, Benassi F, Zappasodi F, Gialloreti LE, Palermo M, Seri S, Rossini PM. Auditory sensory processing in autism: a magnetoencephalographic study, 647
Tedeschi G. *See* Seifritz E
Tennakoon L. *See* Fannon D
Teo Y-Y. *See* Tan E-C
Tepest R, Wang L, Miller MI, Falkai P, Csernansky JG. Hippocampal deformities in the unaffected siblings of schizophrenia subjects, 1234
Thase ME. *See* Gelenberg AJ; Rush AJ
Thayer JF. *See* Ingjaldssoon JT
Thiel T. *See* van Elst LT
Thomas EA. *See* Dean B
Thomas EA, Laws SM, Sutcliffe JG, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN. Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype, 136
Tiihonen J. *See* Joyal CC
Tiihonen J, Hallikainen T, Ryynänen O-P, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial, 1241
Tingström A. *See* Wennström M
Toga AW. *See* Levitt JG
Tohen M. *See* Woods SW
Toivonen P. *See* Tiihonen J
Tolbert LM, Russell DS, Duman RS. Norepinephrine activates extracellular-regulated kinase in cortical neurons, 983
Treasure J. *See* Uher R
Trivedi MH. *See* Gelenberg AJ; Rush AJ
Tronche F. *See* Morozov A
Trost WT. *See* Steffens DC
Tsuang MT. *See* Glatt SJ; Smoller JW; Takahashi S
Tuchman M. *See* Gibson KM
Tupler LA. *See* Vythilingam M
Tuulio-Henriksson A. *See* Johnson JK
Tuulio-Henriksson A, Arajärvi R, Partonen T, Haukka J, Varilo T, Schrek M, Cannon T, Lönnqvist J. Familial loading associates with impairment in visual span among healthy siblings of schizophrenia patients, 623

Ubbiali A. *See* Cavallaro R
Uchitomi Y. *See* Matusoka Y
Uher R, Brammer MJ, Murphy T, Campbell IC, Ng VW, Williams SCR, Treasure J. Recovery and chronicity in anorexia nervosa: brain activity associated with differential outcomes, 934
Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption, 840
Underwood MD. *See* Lira A

Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar CR. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma, 947
Valdizán EM, Gutierrez O, Pazos A. Adenylate cyclase activity in postmortem brain of suicide subjects: reduced response to b-adrenergic stimulation, 1457
Van Broeckhoven C. *See* Claes S
van der Gugten J. *See* de Jongh R
van Elst LT, Hesslinger B, Thiel T, Geiger E, Haegele K, Lemieux L, Lieb K, Bohus M, Hennig J, Ebert D. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study, 163
van Erp TGM. *See* Kieseppä T
van Kammen DP. *See* Condray R
Van Patten SL. *See* Wilens TE
Varilo T. *See* Tuulio-Henriksson A
Verhaagen J. *See* Eisch AJ
Verhoeff NPLG. *See* Kugaya A
Vermetten E. *See* Bremner JD; Schmahl CG
Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder, 693
Vezina LG. *See* Gibson KM
Vilkman H. *See* Joyal CC
Villafuerte RA. *See* Kaufman MJ; Silveri MM
Villafuerte S. *See* Claes S
Volk CLE. *See* Pierri JN
Volkow ND, Insel TR. What are the long-term effects of methylphenidate treatment?, 1307=ED
Vollenweider FX. *See* Ludewig K
Vollmayr B, Simonis C, Weber S, Gass P, Henn F. Reduced cell proliferation in the dentate gyrus is not correlated with the development of learned helplessness, 1035
von Bardeleben U. *See* Seifritz E
Vythilingam M. *See* Bremner JD; Vermetten E
Vythilingam M, Charles HC, Tupler LA, Blitchington T, Kelly L, Krishnan KRR. Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study, 744

Wagner V. *See* Müller JL
Wahlbeck K. *See* Tiihonen J

Wallace-Black D. *See* Bolaños CA
Walsh BT, Zimmerli E, Devlin MJ, Guss J, Kissileff HR. A disturbance of gastric function in bulimia nervosa, 929
Wan Y-J Y. *See* Perlis RH
Wang L. *See* Tepest R
Wang X. *See* Yang J
Wassermann EM. *See* Smith MJ; Speer AM
Watanabe H. *See* Shimizu E
Weber S. *See* Vollmayr B
Wei J. *See* Yang J
Weinberger DR. *See* Winterer G
Weiner MW. *See* Neylan TC
Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Caspi A, Yasvizky R, Mark M, Knobler HY, Nahon D, Davidson M. Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophrenia, 655
Wellek S. *See* Schumann G
Wennström M, Hellsten J, Ekdahl CT, Tingström A. Electroconvulsive seizures induce proliferation of NG2-expressing glial cells in adult rat hippocampus, 1015
Wernicke C, Samochowiec J, Schmidt LG, Winterer G, Smolka M, Kucharska-Mazur J, Horodnicki J, Gallinat J, Rommelspacher H. Polymorphisms in the N-methyl-D-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits, 922
Westin C-F. *See* Kubicki M
Wexler BE. *See* Donegan NH
Whellan DJ. *See* Joynt KE
White FJ. *See* Brandon CL
White T, Andreasen NC, Nopoulos P, Magnotta V. Gyrification abnormalities in childhood- and adolescent-onset schizophrenia, 418
Whitehead RE. *See* Altar CA
Wible CG. *See* Kubicki M
Wieman S. *See* Schumann G
Wilens TE, Biederman J, Wozniak J, Gunawardene S, Wong J, Monuteaux M. Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically relevant adults, 1
Wilens TE, Prince JB, Spencer T, Van Patten SL, Doyle R, Girard K, Hammerness P, Goldman S, Brown S, Biederman J. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder, 9
Wiley J. *See* Sautter FJ
Willeit M, Praschak-Rieder N, Zill P, Neumeister A, Ackenheil M, Kasper S, Bondy B. C825T polymorphism in the G protein b3-subunit gene is associated with seasonal affective disorder, 682
Williams SCR. *See* Kumari V; Uher R
Willis MW. *See* Speer AM
Willour VL. *See* McInnis MG
Winterer G. *See* Gallinat J; Wernicke C
Winterer G, Coppola R, Egan MF, Goldberg TE, Weinberger DR. Functional and effective frontotemporal connectivity and genetic risk for schizophrenia, 1181
Winters B. *See* Morgan CA III
Wolfer DP. *See* Zörner B
Wong J. *See* Wilens TE
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine verus placebo in the symptomatic acute treatment of the schizophrenic prodrome, 453
Wörtwein G. *See* Altar CA
Wozniak J. *See* Wilens TE
Wright CI, Martis B, McMullin K, Shin LM, Rauch SL. Amygdala and insular responses to emotionally valenced human faces in small animal specific phobia, 1067

Xhang D. *See* Yang J
Xu K. *See* Gallinat J

Yaffe K. *See* Penninx BWJH
Yaffe K, Edwards ER, Lui L-Y, Zmuda JM, Ferrell RE, Cauley JA. Androgen receptor CAG repeat polymorphism is associated with cognitive function in older men, 943
Yamashita I. *See* Zhou S-Y
Yamawaki S. *See* Matusoka Y; Morinobu S
Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X, Zhang H, Kong Q, Li X, Liu C, Xhang D, Zhou M, Yu Y, Liu S, Ma D, Wei J, Zhang D. Association study of the human FZD3 locus with schizophrenia, 1298
Yankowitz J. *See* Kelser SR
Yara K. *See* Takahashi S
Yasvizky R. *See* Weiser M
Yehuda R. *See* Neylan TC
Yona I. *See* Bonne O
Young AH. *See* Martin-Ruiz CM
Young FK. *See* Potkin SG
Yu S-Y. *See* Takahashi S
Yu Y. *See* Yang J

Zacher C. *See* Zörner B
Zack JA. *See* Cole SW
Zajecka J. *See* Gelenberg AJ
Zandi PP. *See* McInnis MG
Zappasodi F. *See* Tecchio F
Zaudig M. *See* Pogarell O
Zeitzer JM. *See* Salomon RM
Zeng SM. *See* Kelser SR
Zhang D. *See* Yang J
Zhang H. *See* Yang J
Zhou M. *See* Lira A; Yang J
Zhou S-Y, Suzuki M, Hagino H, Takahashi T, Kawasaki Y, Nohara S, Yamashita I, Seto H, Kurachi M. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia, 427
Zill P. *See* Willeit M
Zimmerli E. *See* Walsh BT
Zipursky RB. *See* Woods SW
Zmuda JM. *See* Yaffe K
Zoghbi SS. *See* Kugaya A
Zörner B, Wolfer DP, Brandis D, Kretz O, Zacher C, Madani R, Grunwald I, Lipp H-P, Klein R, Henn FA, Gass P. Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than "depressive," 972

Subject Index to Volume 54

Abandonment
  borderline personality disorder and, 142
Adenylate cyclase
  in postmortem brain, 1457
Adolescents
  drug abuse in, 655
  methylphenidate for
    behavioral responses affected by, 1317
    neuronal changes secondary to, 1338
  schizophrenia in, 418
β-Adrenergic receptors, 1457
Adrenocorticotrophin
  responses of, to corticotropin-releasing hormone in substance abusers, 872
Affect
  in treatment-resistant depression, 777
Aggression
  catechol-O-methyltransferase gene polymorphisms and, 34
Alcohol abuse
  heart rate variability in, 1427
Alcohol dependence
  protein tyrosine kinase fyn genetic variations in, 1422
Alcoholism
  N-methyl-D-aspartate receptor polymorphisms and, 922
  nocturnal melatonin secretion in, 1437
  sleep disturbances in, 1437
Allostatic load
  mood disorders and, 200
Alternative splicing
  in nervous system, 771
Alzheimer's disease
  apolipoprotein D levels in prefrontal cortex in, 136
  depression in, 353
Amphetamines
  chronic use of, 105
  sensitization, hallucinatory-like behaviors and, 105
  withdrawal from
    clozapine attenuation of somatic and afferent effects of, 1249
    depression secondary to, 49
Amygdala
  anxiety disorders and, 1067
  hyperreactivity of, in borderline personality disorder, 1284
  infant vocalization responses, 1367
  schizophrenia and, 1302
  thyroid hormones, antidepressant drug targeting of, 1049
  volumetric study of
    in cancer survivors, 736
    in schizophrenia, 1302
Androgen receptor CAG repeat polymorphism
  cognitive function in older men and, 943
Animal models
  amphetamine withdrawal, 49
  antidepressant drug targeting of thyroid hormones, 1049
  antidepressant penetration in mice with P-glycoprotein gene disruption, 840
  anxiety, 552
  brain-derived neurotrophic factor, 59, 703
  clozapine attenuation of somatic and afferent effects of nicotine and amphetamine withdrawal, 1249
  depression
    amphetamine withdrawal as cause of, 49
    forebrain-specific trkB-receptor knockout mice, 972
  early-life stressors effect, 727
  electroconvulsive seizure upregulation of β-catenin expression, 1006
  immobilization stress effects on protein phosphatase 2A, 1060
  lithium effects on auditory gating, 847
  methylphenidate effects on behavior, 1330
  neonatal ventral hippocampal—lesioned, prepulse inhibition deficits in startle reflex of, 1162
  serotonin transporter gene, 953
Anorexia nervosa
  brain-derived neurotrophic factor levels in, 485
  chronicity in, 934
  course of, 934
  neural correlates of, 934
Anterior cingulate
  choline metabolite decreases, in selective serotonin reuptake inhibitor discontinuation syndrome, 534
Anterior limb of internal capsule
  in schizophrenia, 427
Antidepressants
  apolipoprotein E epsilon4 allele and, 665
  brain-derived neurotrophic factor affected by, 70, 703
  discontinuation of, 1105
  light therapy for, 687
  penetration into mice with abcb1ab P-glycoprotein gene disruption, 840
  thyroid hormones affected by, 1049
  withdrawal, 1105
Antipsychotic medications
  N-acetylaspartate abnormalities caused by, 587
Antisense RNA amplification, 413
Anxiety
  amygdala's role in, 1067
  animal models of, 552

Abbreviations:
ed: editorial
comm: commentary
corr: correspondence

© 2003 Society of Biological Psychiatry

0006-3223/03/$30.00
PII S0006-3223(03)01164-8

assessments of, 552
corticotropin-releasing hormone gene variants and, 1376
serotonin transporter gene phenotype variation and, 953
Apolipoprotein D
prefrontal cortex levels of, in schizophrenia, 136
in schizophrenia, 136
Apolipoprotein E
epsilon4 allele, antidepressant efficacy and, 665
genotypes, 665, 674
in schizophrenia, 136, 616
schizophrenia and, 136
subcortical vascular lesions and, 674
Attention deficit hyperactivity disorder
bipolar disorder and
bupropion for, 9
comorbid presentation of, 1
inhibitory motor control in, 1345
methylphenidate for. *See* Methylphenidate
Auditory gating
lithium effects on, 847
Auditory steady-state field generators
in schizophrenia, 1149
Autism
auditory sensory processing in, 647
magnetoencephalography evaluation of, 647
mismatch fields in, 647
proton magnetic resonance spectroscopy evaluations, 1355

Basal ganglia
abnormalities of, in major depression, 744
membrane phospholipid abnormalities of, in schizophrenia, 491
Basal-corticofrontal circuits
in obsessive-compulsive disorder, 437
in schizophrenia, 437
Behavior
aggressive, 34
methylphenidate effects on, 1330
suicidal, 444
Behavioral disturbances
drug abuse and, 655
in succinic semialdehyde dehydrogenase deficiency, 763
Behavioral inhibition
corticotropin-releasing hormone and, 1376
Benzodiazepine receptors
in major depression, 792
Bipolar disorder
attention deficit hyperactivity disorder and
bupropion for, 9
comorbid presentation of, 1
conditional analysis in, 1265
corpus callosum abnormalities in, magnetic resonance imaging of, 1294
depression and, 181–comm
emotion processing abnormalities in, 515
genomic-wide scan in, 1265
left hemispheric white matter volume in, 896
mood regulation in, state and trait influences on, 1274
regional cerebral blood flow evaluations in, 1274
schizophrenia and, 847
Blood—brain barrier, 840
Borderline personality disorder
abandonment and, 142
amygdala hyperreactivity in, 1284
Brain
conditional mutagenesis for studying, 1125
development of, 1312
disgust-inducing pictures activation of, in obsessive-compulsive disorder, 751
functional development of, 1312
magnetic resonance imaging volumetric measurements, in schizophrenia, 608
monoamine oxidases in, 1099
mood disorders effect on, 338
postmortem, adenylate cyclase activity in, 1457
regional transcranial magnetic stimulation effects, 818, 826
response to progesterone, in premenstrual syndrome, 757
S-adenosyl-L-methionine effects on, 833
Brain-derived neurotrophic factor
animal models of, 59, 703
antidepressant effects on, 70, 703
depression and, 70, 703, 994
eating disorders and, 485
electroconvulsive seizures effect on, 702
estradiol effects on, 59
5-HT2A agonists effect on, 59
stress effects on, 59
in ventral midbrain—nucleus accumbens pathway, 70, 703, 994
Bulimia nervosa
brain-derived neurotrophic factor levels in, 485
gastric function disturbances in, 929
Bupropion
attention deficit hyperactivity disorder and bipolar disorder treated with, 9
dopamine transporter activity of, 800

CAG repeat polymorphisms, androgen receptor
cognitive function in older men and, 943
Cancer
depression and
diagnosis of, 283
disease progression, 269
mechanisms of, 269
treatment of, 283
mood disorders and, 191–comm
survivors of
amygdala volumetric study in, 736
intrusive memories in, 736
Cardiovascular disease
depression and
mechanisms of, 248
risk reduction, 187–comm
Catechol-O-methyltransferase polymorphisms
aggressive behavior and, 34
G1947A, 40

prefrontal P300 and, 40
V158M, 34
β-Catenin
electroconvulsive seizure upregulation of, in rat hippocampus, 1006
Cavum septi pellucidi
in Tourette syndrome, 76
Cerebral blood flow
regional, in posttraumatic stress disorder, 1077
during regional transcranial magnetic stimulation, 818, 826
Cerebral perfusion
in posttraumatic stress disorder, 1077
Cerebrospinal fluid
hypocretin-1 levels in, diurnal variation of, 96
Cerebrovascular disease
geriatric depression and, 674
Children
reading disability in, 25
schizophrenia
gyrification abnormalities in, 418
sexual abuse in, hypothalamic-pituitary-adrenal axis assessments after, 710
socially withdrawn
mismatch negativity in, 17
Choline
in major depression, 1399
in obsessive-compulsive disorder, 1399
Cingulate fasciculus
integrity disruption of, in schizophrenia, 1171
Clozapine
amphetamine withdrawal and, 1249
nicotine withdrawal and, 1249
Cocaine
locomotor sensitization to, disulfiram effects on, 915
Cognitive function
androgen receptor CAG repeat polymorphism effects on, in older men, 943
Conditional mutagenesis
brain studies using, 1125
Coronary artery disease
depression and, 227
Coronary heart disease
depression and
mortality and morbidity in, 241
treatment of, 262
Corpus callosum abnormalities
magnetic resonance imaging of, in bipolar disorder, 1294
Cortical neurons
norepinephrine activation of mitogen-activated protein kinase cascade in, 983
Corticotropin-releasing hormone
anxiety and, 1376
behavioral inhibition and, 1376
genetic markers, 1376
light-enhanced startle and, 1041
in posttraumatic stress disorder, 1382
stress hormone responses to, 872
Corticotropin-releasing hormone binding protein
major depression and, 867
Cortisol
hippocampal N-acetylaspartate levels and, 1118
oxytocin and social support suppression of, in psychosocial stress, 1389
Cortisol stress response
in infants, 719
C825T polymorphism
in seasonal affective disorder, 682

Dementia
in schizophrenia, 1222
Dentate gyrus. *See also* Hippocampus
cell proliferation reductions, learned helplessness and, 1035
prenatal stress effects on neurogenesis of, 1025
Depression. *See also* Major depression
affect in, neural abnormalities during cognitive generation of, 777
in Alzheimer's disease, 353
amphetamine withdrawal and, 49
animal models of
amphetamine withdrawal as cause of, 49
forebrain-specific trkB-receptor knockout mice, 972
antidepressant withdrawal effects, 1105
benzodiazepine receptors in, 792
bipolar disorder and, 181–comm
brain-derived neurotrophic factor levels in, 70, 994
cancer and
diagnosis of, 283
disease progression, 269
mechanisms of, 269
treatment of, 283
cardiovascular disease and
mechanisms of, 248
risk reduction, 187–comm
coronary artery disease and, 227
coronary heart disease and
mortality and morbidity of, 241
treatment of, 262
diabetes mellitus and, 317
dorsal raphe nucleus changes in serotonin transporter-deficient mice and, 960
in elderly
antidepressant efficacy for, apolipoprotein E epsilon4 allele effects on, 665
cerebrovascular disease and, 665
inflammatory markers and, 566
orbitofrontal cortex volume reductions associated with, 529
electroconvulsive seizures for. *See* Electroconvulsive seizures
emotion processing abnormalities in, 515
in epilepsy, 388
geriatric, orbitofrontal cortex volume reductions in, 529
human immunodeficiency virus progression and, 295
hypocretin-1 diurnal variations in, 96
medical illness and
epidemiology of, 216

National Institute of Medical Health perspective, 184–comm
obesity and, 330
in Parkinson's disease, 363
persistent pain and, 399
poststroke, 376
Pyk2 and, 540
S-adenosyl-L-methionine for, 833
serotonin transporter gene phenotype variation and, 953
treatment of
in cancer patients, 283
in heart disease patients, 262
trkB receptor and, 994
tryptophan levels and, 906
ventral midbrain—nucleus accumbens pathways in, brain-derived neurotrophic factor in, 70, 703, 994
Diabetes mellitus
depression and, 317
Discontinuation syndrome
selective serotonin reuptake inhibitors, 534
Disgust
obsessive-compulsive disorder and, 751
Disulfiram
locomotor sensitization to cocaine affected by, 915
Dopamine
pathological gambling and, 474
raclopride and, 1193
Dopamine transporter
bupropion activity at, 800
Dopamine-β-hydroxylase
disulfiram effects on, 915
Dorsal raphe nucleus
of serotonin transporter-deficient mice, 960
DRD4
schizophrenia and, 629
Drug abuse
in adolescents, 655
behavior disturbances and, 655

Early-life stressors
magnetic resonance spectroscopy evaluations of, 727
Eating disorders. *See also* Anorexia nervosa; Bulimia nervosa
brain-derived neurotrophic factor levels in, 485
Elderly
cognitive function, androgen receptor CAG repeat polymorphism effects on, 943
depression in
antidepressant efficacy for, apolipoprotein E epsilon4 allele effects on, 665
cerebrovascular disease and, 665
inflammatory markers and, 566
orbitofrontal cortex volume reductions associated with, 529
Electroconvulsive seizures
brain-derived neurotrophic factor and, 702
β-catenin expression upregulated by, 1006
glial progenitor cell proliferation induced by, 1015
Emotion
dysregulation, amygdala hyperreactivity effects on, 1284
perception
neurobiology of, 504, 515
psychiatric disorder-related abnormalities, 515
processing abnormalities
in bipolar disorder, 515
in depression, 515
in schizophrenia, 515
in psychopaths, 152
Epilepsy
depression in, 388
Estradiol
brain-derived neurotrophic factor expression and, 59
Event-related brain potentials, 1134, 1345

Familial loading
in schizophrenia, 623
Fear conditioning
neural cell adhesion molecule polysialylation modulated by, 599
spatial memory consolidation by, 599
Fear-potentiated startle
light-enhanced startle vs., 1041
Fluoxetine
agitation caused by, 879
insomnia caused by, 879
serotonin transporter gene polymorphisms and, 879
Forebrain-specific trkB-receptor knockout mice, 972
Frontal cortex
apolipoprotein E levels, in schizophrenia, 616
Frontotemporal connectivity
schizophrenia risks and, 1181
Functional magnetic resonance imaging
emotion processing abnormalities in psychopaths evaluated by, 152
fyn
genetic variations of, in alcohol dependence, 1422
FZD3 locus
in schizophrenia, 1298

G proteins
β3-subunit C825T polymorphism, in seasonal affective disorder, 682
G1947A, 40
Gambling, pathological
sensory gating disruptions in, 474
Gamma-hydroxybutyric aciduria. *See* Succinic semialdehyde dehydrogenase deficiency
Gastric function disturbances
in bulimia nervosa, 929
Gene polymorphisms
A218, in tryptophan hydroxylase gene, 465
catechol-O-methyltransferase, in aggressive personality, 34
serotonin transporter
fluoxetine and, 879
functional, 687
Geriatric depression
cerebrovascular disease and, 674
orbitofrontal cortex volume reductions in, 529

subcortical lesions in, 529
Glial progenitor cells
electroconvulsive seizure-induced proliferation of, 1015
Glycine, 1162
Glycine transporter inhibitor, 1162
Gyrification
in schizophrenia, 418

Hallucinations
amphetamine sensitization and, 105
Heart rate variability
in alcohol abuse, 1427
Heroin dependence
opioid maintenance treatment for, 854
Hippocampus. *See also* Dentate gyrus
cell proliferation reductions, learned helplessness and, 1035
deformities of, in schizophrenia, 1234
electroconvulsive seizure upregulation of β-catenin expression in, 1006
N-acetylaspartate
abnormalities in, secondary to antipsychotic medications, 587
cortisol levels correlated with, 1118
neural cell adhesion molecule polysialylation, fear conditioning effects on, 599
neurogenesis, major depression and, 499
rat models
electroconvulsive seizure upregulation of β-catenin expression in, 1006
electroconvulsive seizure-induced proliferation of glial progenitor cells in, 1015
volume
paroxetine effects on, 693
posttraumatic stress disorder-related reductions in, 1118
5-HT2A agonists
brain-derived neurotrophic factor expression and, 59
Human immunodeficiency virus
depression effects on, 295
mood disorders in
diagnosis of, 307
prevalence of, 307
treatment of, 307
psychological risk factors for, 1444
stress effects on, 295
Hydrocortisone
serotonin $_{1A}$ receptors and, 890
Hypocretin
cerebrospinal fluid, 96
diurnal variation of, 96
narcolepsy and, 87
Hypothalamic-pituitary-adrenal axis
in women with and without childhood sexual abuse and posttraumatic stress disorder, 710
^{123}Iiomazenil single photon emission computed tomography, 792

Immobilization stress
protein phosphatase 2A affected by, 1060
Indoleamine-2,3-dioxygenase, 906
Infants
cortisol stress response in, 719
vocalization by, amygdala response to, 1367
Inflammatory markers
depression in elderly and, 566
Information processing
deficits of, in schizophrenia, 121
G1947A catechol-O-methyltransferase polymorphism and, 40
Insula
specific phobia responses, 1067
Interferon-alpha
tryptophan metabolism affected by, 906
Internal capsule, in schizophrenia
anterior limb of, 427
asymmetry of, 427
Intron 2 polymorphisms
suicide and, 884
Intrusive memories
in cancer survivors, 736

Kynurenine, 906

Lamotrigine
schizophrenia treated with, 1241
Lateral septum
Pyk2 antidepressant effect in, 540
Learned helplessness
dentate gyrus cell proliferation and, 1035
Left hemispheric white matter
in bipolar disorder, 896
Levels-of-processing
word recognition in schizophrenia affected by, 1154
Light therapy, 687
Light-enhanced startle
corticotropin-releasing hormone in, 1041
fear-potentiated startle vs., 1041
Lithium
auditory gating measures altered by, 847

Magnetic resonance imaging
amygdala volume effects on schizophrenia, 1302
brain measurements and outcome in schizophrenia, 608
cingulate fasciculus integrity disruption in schizophrenia evaluated by, 1171
corpus callosum abnormalities in bipolar disorder evaluated by, 1294
left hemispheric white matter in bipolar disorder evaluated using, 896
Magnetic resonance spectroscopy
anterior cingulate choline metabolite decreases in selective serotonin reuptake inhibitor discontinuation syndrome evaluated using, 534
early-life stressors effect evaluated by, 727
membrane phospholipids in basal ganglia of schizophrenia patients, 491
^{31}P, 491, 833
proton

autism evaluations, 1355
focal and lateralized subcortical abnormalities in major depression evaluated by, 744
schizophrenia evaluations using, 587
Magnetoencephalography
autism evaluations, 647
Major depression. *See also* Depression
benzodiazepine receptors in, 792
brain-derived neurotrophic factor levels in, 70
cellular plasticity hypothesis of, 499
choline in, 1399
corticotropin-releasing hormone binding protein and, 867
genetics of, 867
hippocampal neurogenesis and, 499
medical illness and, 216
monoamine oxidase inhibitors for, 793
nefazodone for preventing recurrence of, 806
neurogenesis hypothesis of, 499
psychometric evaluations of, 573
Quick Inventory of Depressive Symptomatology evaluations, 573
recurrence of, 806
serotonin $_{1A}$ receptor decreases in, hydrocortisone effects on, 890
subcortical abnormalities in, 744
Medical illness. *See also specific illness*
depression and, 216
major depression and, 216
mood disorders and
National Cancer Institute perspective, 191–comm
National Institute of Medical Health perspective, 184–comm
overview of, 177–ed
patient needs, 181–comm
Melatonin
abnormal secretion of, in alcoholism, 1437
Membrane phospholipids
in basal ganglia of schizophrenia patients, 491
Memory
intrusive memories, in cancer survivors, 736
spatial, 599
Messenger ribonucleic acid, 413
Methylphenidate
behavioral effects of, 1330
behavioral responses to emotional stimuli altered by, 1317
long-term effects of, 1307–ED, 1317
neuronal changes secondary to, 1338
plasticity induced by, 1310–ED
response inhibition improvements using, 1465
Mice
knockout, forebrain-specific trkB-receptor, 972
serotonin transporter gene-deficient
abnormal behavioral phenotypes, 953
dorsal raphe nucleus changes, 960
Mismatch fields
in autism, 647
Mismatch negativity
in social withdrawal, 17
Mitogen-activated protein kinase cascade
norepinephrine activation of, 983
Monoamine oxidase inhibitors
major depression treated with, 793
selegiline, 1099
Mood challenge
in bipolar disorder, 1274
Mood disorders. *See also specific disorder*
allostatic load and, 200
brain effects, 338
cancer and, 191–comm
in human immunodeficiency virus
diagnosis of, 307
prevalence of, 307
treatment of, 307
medical illness and
National Cancer Institute perspective, 191–comm
National Institute of Medical Health perspective, 184–comm
overview of, 177–ed
patient needs, 181–comm
neuroimaging studies of, 338
public health concerns, 177–ed
socioeconomic burden of, 208
Morbidity
depression and coronary heart disease, 241
Mortality
depression and coronary heart disease, 241
Motor cortex
abnormal luteal phase excitability of, in premenstrual syndrome, 757
regional transcranial magnetic stimulation in, 818, 826
mRNA expression profiling, 1212

N-Acetylaspartate
antipsychotic medications effect on, 587
hippocampal, cortisol levels correlated with, 1118
N-Acetyl-L-aspartate, 744
Narcolepsy
hypocretins in, 87
orexins in, 87
National Cancer Institute, 191–comm
National Institute of Mental Health, 184–comm, 1265
Nefazodone
major depression recurrence prevented by, 806
Neopterin, 906
Nervous system
alternative splicing in, 771
Neural cell adhesion molecules
fear conditioning effects on, 599
Neural systems
emotion perception and, 504, 515
Neurofilament protein, 111
Neurogenesis
dentate gyrus, prenatal stress effects on, 1025
hippocampal, 499
major depression and, 499
Neurologic disease

single-cell molecular biology applications, 413
Neuronavigated repetitive transcranial magnetic stimulation, 862
Neuropeptide-Y
posttraumatic stress disorder and, 1087
trauma exposure and, 1087
Nicotine withdrawal
clozapine attenuation of somatic and afferent effects of, 1249
Nicotinic receptor
expression of, in prefrontal cortex in schizophrenia, 1222
Nightmares, 1092
N-methyl-D-aspartate receptor polymorphisms
alcoholism and, 922
Norepinephrine
mitogen-activated protein kinase cascade activated by, 983
NOTCH4 gene
in schizophrenia, 129

Obesity
depression and, 330
Obsessive-compulsive disorder
basal-corticofrontal circuits in, 437
disgust-inducing pictures in, brain activation by, 751
medial thalamic choline in, 1399
serotonin transporters in, 1406, 1414
Olanzapine
schizophrenic prodrome treated with, 453
Opioids
injectable, 854
maintenance therapy, for heroin dependence, 854
Orbitofrontal cortex volume
in geriatric depression, 529
Orexins
cerebrospinal fluid, 96
diurnal variation of, 96
narcolepsy and, 87
Oxytocin
social support and, stress responses affected by, 1389

P300, 40
Pain
depression and, 399
Parkinson's disease
depression in, 363
Paroxetine
hippocampal volume and, 693
interferon-alpha effects on tryptophan metabolism and, 906
verbal declarative memory affected by, 693
Pathological gambling
sensory gating disruptions in, 474
Periodic leg movements in sleep, 1092
Personality
aggressive, catechol-O-methyltransferase polymorphisms and, 34
P-glycoprotein, 840
Positron emission tomography
bupropion activity at dopamine transporter measured by, 800
[^{11}C]McN 5652, 1414
hydrocortisone effects on serotonin$_{1A}$ receptors in major depression evaluated using, 890
regional transcranial magnetic stimulation effects
in prefrontal cortex, 826
in primary motor cortex, 818
serotonin transporters in obsessive-compulsive disorder evaluated by, 1414
Posttraumatic stress disorder
cerebral perfusion in, 1077
corticotropin-releasing hormone in, 1382
cortisol levels in, 1118
hippocampal volume reductions in, 1118
immediate treatment of, 947
intrusive memories in, 736
neuropeptide-Y and, 1087
paroxetine effects on verbal declarative memory and hippocampal volume in, 693
propranolol for, 947
psychotic symptoms and, 1382
regional cerebral blood flow in, 1077
sleep disturbances in, 1092
in women, hypothalamic-pituitary-adrenal axis assessments after, 710
Prefrontal cortex
amphetamine sensitization of hallucinatory-like behaviors and, 105
apolipoprotein D levels, in Alzheimer's disease, 136
pyramidal neurons, in schizophrenia, 111
regional transcranial magnetic stimulation, 826
schizophrenia, 111, 1222
Prefrontal noise, 40
Premenstrual syndrome
brain response to progesterone in, 757
Prenatal stress
dentate gyrus neurogenesis affected by, 1025
Prepulse inhibition
deficits, glutamatergic neurotransmission impairments as cause of, 1162
in schizophrenia, 121
Primary motor cortex
regional transcranial magnetic stimulation, 818
Prodrome, schizophrenic
olanzapine for, 453
Progesterone
brain response to, in premenstrual syndrome, 757
Protein phosphatase 2A
immobilization stress effects on, 1060
Protein tyrosine kinase fyn
genetic variations of, in alcohol dependence, 1422
Proton magnetic resonance spectroscopy
autism evaluations, 1355
focal and lateralized subcortical abnormalities in major depression evaluated by, 744
schizophrenia evaluations using, 587
Psychopathy
emotion processing abnormalities in cortical and subcortical regions, 152

Psychosis
posttraumatic stress disorder and, 1382
Pyk2
antidepressant effect of, in lateral septum, 540
Pyramidal neurons
prefrontal cortex, in schizophrenia, 111

Quick Inventory of Depressive Symptomatology, 573

Raclopride
dopamine release and, 1193
Reading disability
neural basis for, 25
outcome of, 25
Regional cerebral blood flow
in bipolar disorder, 1274
in posttraumatic stress disorder, 1077
Regional transcranial magnetic stimulation
cerebral blood flow during, 818, 826
prefrontal cortex, 826
primary motor cortex, 818
Response inhibition
methylphenidate effects on, in attention-deficit/hyperactivity disorder, 1465
RNA expression profiling, 1212

S-adenosyl-L-methionine
depression treated with, 833
Schizoaffective disorder
suicidal risks in, 444
Schizophrenia
adolescent-onset, 418
amygdala and, 1302
apolipoprotein D levels in, 136
apolipoprotein E levels in, 136, 616
auditory steady-state field generators in, 1149
basal ganglia, membrane phospholipid abnormalities in, 491
basal-corticofrontal circuits in, 437
bipolar disorder and, 847
brain measurements in, 608
chaos and, 661–corr
childhood-onset, 418
cingulate fasciculus integrity disruption in, 1171
dementia in, 1222
DRD4 associated with, 629
emotion processing abnormalities in, 515
familial loading in, 623
family-based association study of, 129
frontotemporal connectivity and, 1181
FZD3 locus in, 1298
genetics of, 1181
hippocampal deformities in, 1234
information-processing deficits in, 121
internal capsule in
anterior limb of, 427
asymmetry of, 427
lamotrigine for, 1241
magnetic resonance imaging of, 608
N-acetylaspartate abnormalities in, secondary to antipsychotic medications, 587
NOTCH4 gene in, 129
prefrontal cortex in
apolipoprotein D levels in, 136
nicotinic receptor expression in, 1222
pyramidal neurons, 111
prepulse inhibition deficits in, 121
prodrome, olanzapine for, 453
risks
frontotemporal connectivity and, 1181
schizotypal symptoms and, 1200
schizotypal symptoms and, 1200
semantic network in, automatic activation of, 1134
serotonin receptor 2C decreases in, 1212
suicidal risks in, 444
temporal lobe function and, 1149
tumor necrosis factor-α gene promoter polymorphisms in, 1205
visual span impairment in, familial loading effects on, 623
word recognition in, levels-of-processing effect on, 1154
Schizotypy
schizophrenia risks and, 1200
Seasonal affective disorder
G protein β3-subunit C825T polymorphism in, 682
Selective serotonin reuptake inhibitors
discontinuation syndrome, 534
Selegiline, 1099
Semantic network
in schizophrenia, 1134
Septum, lateral
Pyk2 antidepressant effect in, 540
Serotonin $_{1A}$ receptor
hydrocortisone effects on, in major depression, 890
major depression and, 890
Serotonin receptor 2C
in schizophrenia, 1212
Serotonin transporter
in obsessive-compulsive disorder, 1406, 1414
Serotonin transporter gene
behavioral phenotypes of, 953
mouse models of
abnormal behavioral phenotypes, 953
dorsal raphe nucleus changes, 960
polymorphisms
fluoxetine and, 879
functional, 687
Serotonin transporter gene promoter polymorphisms
fluoxetine and, 879
suicide and, 884
Sexual abuse
childhood, hypothalamic-pituitary-adrenal axis assessments after, 710
in women, 710
Single photon emission computed tomography
^{123}Iiomazenil, 792
Single-cell molecular biology
neurologic disease diagnosis and treatment uses of, 413

Sleep deprivation
serotonin transporter gene functional polymorphism in, 687
Sleep disturbances
in alcoholism, 1437
periodic leg movements in sleep, 1092
in posttraumatic stress disorder, 1092
Social support
oxytocin and, stress responses affected by, 1389
Social withdrawal
in children, 17
mismatch negativity in, 17
Spatial memory
fear conditioning effects on, 599
Specific phobia
amygdala responses in, 1067
insular responses in, 1067
Startle reflex
prepulse inhibition deficits of, 1162
Stress
brain-derived neurotrophic factor expression and, 59
human immunodeficiency virus progression and, 295
immobilization, protein phosphatase 2A affected by, 1060
oxytocin and social support effects on, 1389
prenatal, neurogenesis in dentate gyrus affected by, 1025
Stressors
in infants, 719
magnetic resonance spectroscopic imaging study of, 727
Stroke
depression after, 376
Subcortical lesions
in geriatric depression, 529
Substance abuse
corticotropin-releasing hormone in, stress hormone responses to, 872
Succinic semialdehyde dehydrogenase deficiency
behavioral disturbances in, 763
Suicidal behavior
risks of
in schizoaffective disorder, 444
in schizophrenia, 444
tryptophan hydroxylase in, 465
Suicide
adenylate cyclase activity in postmortem brain, 1457
intron 2 polymorphisms in, 884
serotonin transporter gene promoter polymorphisms and, 884
Superior temporal gyrus
in Turner syndrome, X-monosomy effects on, 636

Thyroid hormones
antidepressant drug targeting of, 1049
Tinnitus
repetitive transcranial magnetic stimulation evaluations of, 862
Tourette syndrome
cavum septi pellucidi in, 76
Transcranial magnetic stimulation
neuronavigated repetitive, 862
regional
in prefrontal cortex, 826
in primary motor cortex, 818
tinnitus evaluations, 862
Trauma
neuropeptide-Y and, 1087
trkB receptor
depression and, 994
knockout mice with forebrain-specific trkB-receptor, 972
Tryptophan
interferon-alpha effects on metabolism of, 906
suicidal behavior and, 465
Tumor necrosis factor-α
depression in elderly and, 566
gene promoter polymorphisms of, in chronic schizophrenia, 1205
Turner syndrome
superior temporal gyrus in, X-monosomy effects on, 636
X-monosomy in, 636
Tyrosine kinases
Pyk2, 540

Ventral midbrain—nucleus accumbens
brain-derived neurotrophic factor in, 70, 703, 994
Verbal declarative memory
paroxetine effects on, 693
V158M, 34

White matter, left hemispheric
in bipolar disorder, 896
Withdrawal
amphetamine, depression secondary to, 49
Women
borderline personality disorder in, 142
posttraumatic stress disorder in, 710
premenstrual syndrome in, 757
sexual abuse in, hypothalamic-pituitary-adrenal axis assessments after, 710

X-monosomy
in Turner syndrome, 636